NPS Pharmaceuticals Price Target Raised to $41.00 at Brean Capital (NPSP)
Brean Capital boosted their price target on shares of NPS Pharmaceuticals (NASDAQ:NPSP) from $36.00 to $41.00 in a research note issued on Thursday, AnalystRatingsNetwork.com reports. Brean Capital’s price objective indicates a potential upside of 16.78% from the stock’s previous close.
In other NPS Pharmaceuticals news, CFO Luke Beshar unloaded 37,874 shares of the company’s stock on the open market in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $30.02, for a total value of $1,136,977.48. Following the transaction, the chief financial officer now directly owns 59,180 shares of the company’s stock, valued at approximately $1,776,584. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of other analysts have also recently weighed in on NPSP. Analysts at Canaccord Genuity raised their price target on shares of NPS Pharmaceuticals from $35.00 to $42.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Separately, analysts at Jefferies Group raised their price target on shares of NPS Pharmaceuticals from $21.00 to $28.00 in a research note to investors on Thursday, November 7th. They now have a “buy” rating on the stock. Three equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. NPS Pharmaceuticals presently has an average rating of “Buy” and an average price target of $37.69.
Shares of NPS Pharmaceuticals (NASDAQ:NPSP) traded up 4.13% during mid-day trading on Thursday, hitting $36.56. The stock had a trading volume of 2,576,010 shares. NPS Pharmaceuticals has a 52 week low of $7.35 and a 52 week high of $35.72. The stock’s 50-day moving average is $26.9 and its 200-day moving average is $25.1. The company’s market cap is $3.733 billion.
NPS Pharmaceuticals (NASDAQ:NPSP) last announced its earnings results on Wednesday, November 6th. The company reported ($0.01) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.02) by $0.01. The company had revenue of $39.20 million for the quarter, compared to the consensus estimate of $38.40 million. During the same quarter last year, the company posted ($0.04) earnings per share. NPS Pharmaceuticals’s revenue was up 45.2% compared to the same quarter last year. On average, analysts predict that NPS Pharmaceuticals will post $-0.21 earnings per share for the current fiscal year.
NPS Pharmaceuticals, Inc (NASDAQ:NPSP) is a clinical-stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.